Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sulindac may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Drugs used in chemotherapy, such as epirubicin, work in different ways to
stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving sulindac together with epirubicin may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving sulindac together with epirubicin
works in treating patients with metastatic malignant melanoma.